SAM
CRNX

Smartleaf Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Smartleaf Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3K Hold
605
– – ﹤0.01% 1944
2026
Q1 		$20.7K Sell
605
-34
-5% -$1.52K ﹤0.01% 1934
2025
Q4 		$30.3K Buy
639
+331
+107% +$14.7K ﹤0.01% 1805
2025
Q3 		$13.4K Buy
308
+202
+191% +$6.46K ﹤0.01% 1994
2025
Q2 		$3.17K Buy
106
+100
+1,667% +$3.09K ﹤0.01% 2192
2025
Q1 		$208 Sell
6
-175
-97% -$6.54K ﹤0.01% 2794
2024
Q4 		$9.17K Buy
181
+25
+16% +$1.4K ﹤0.01% 2025
2024
Q3 		$7.92K Buy
156
+24
+18% +$1.24K ﹤0.01% 1898
2024
Q2 		$5.74K Buy
+132
New +$6.1K ﹤0.01% 1731

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's CRNX Position: Q2 2026 in Review

Smartleaf Asset Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 605 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

Smartleaf Asset Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $30.3K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Smartleaf Asset Management held 605 shares of Crinetics Pharmaceuticals worth $22.3K as of Q2 2026.
  • Smartleaf Asset Management left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1944 holding.
  • Smartleaf Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's Crinetics Pharmaceuticals position peaked at $30.3K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.